Maris Hartmanis Maris Hartmanis is new CEO for BioPhausia
He takes up his position on 9 August. Maris Hartmanis has many years of experience in leading positions in companies in the biotechnology, medical technology and pharmaceutical industries. He was Senior Vice President of Research and Development at Gambro between 2004 and 2008 and has held positions in Gyros, Amersham Biosciences, Pharmacia & Upjohn, Pharmacia and KabiGen.
”I look forward to the opportunity to develop the company further together with an enthusiastic organization!”

 
Novalucol has helped countless Swedes with heartburn over the years. Sugar-free and rapid-acting.
www.novalucol.se  





BioPhausia’s shares are listed on NASDAQ OMX Nordic (Stockholm small cap).
Shares »  Debentures » Warrants » 

View financial calendar » 
View financial reports »  
Please contact us if you have any questions about our products.

Our subsidiaries: